2012
Cost-effectiveness of pharmacologic and invasive therapies for stroke prophylaxis in atrial fibrillation
Solomon MD, Ullal AJ, Hoang DD, Freeman JV, Heidenreich P, Turakhia MP. Cost-effectiveness of pharmacologic and invasive therapies for stroke prophylaxis in atrial fibrillation. Journal Of Cardiovascular Medicine 2012, 13: 86-96. PMID: 22193838, DOI: 10.2459/jcm.0b013e32834f23cf.Peer-Reviewed Original ResearchConceptsCost-effectiveness analysisAtrial fibrillationNonpharmacologic therapiesAtrial fibrillation-related strokeVitamin K antagonistsNew pharmacologic therapiesDirect thrombin inhibitorDevice-based therapiesLeft atrial appendageStroke Risk ProfileHealth policy recommendationsPercutaneous ligationStroke prophylaxisK antagonistsStroke preventionPharmacologic therapySurgical ligationAbnormal heart rhythmAntiplatelet agentsProphylaxis strategiesAtrial appendageRight atriumEndovascular implantationInvasive therapySystemic circulation
2010
Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Annals Of Internal Medicine 2010, 154: 1-11. PMID: 21041570, DOI: 10.7326/0003-4819-154-1-201101040-00289.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAnticoagulantsAtrial FibrillationBenzimidazolesBeta-AlanineCost-Benefit AnalysisDabigatranFibrinolytic AgentsHemorrhageHumansIntracranial HemorrhagesIschemic Attack, TransientMarkov ChainsMyocardial InfarctionQuality-Adjusted Life YearsRisk FactorsSensitivity and SpecificityStrokeWarfarinConceptsHigh-dose dabigatranIncremental cost-effectiveness ratioNonvalvular atrial fibrillationLow-dose dabigatranCost-effectiveness ratioAtrial fibrillationIschemic strokeCost of dabigatranIntracranial hemorrhageClinical trialsOral direct thrombin inhibitorVeterans Affairs Health Services ResearchSingle randomized clinical trialAdjusted-dose warfarinStudies of anticoagulationPatients 65 yearsRE-LY trialDirect thrombin inhibitorRandomized clinical trialsAmerican Heart AssociationQuality-adjusted life expectancyQuality-adjusted survivalBase-case analysisHealth services researchStroke prevention